| 1 |
35421448 | Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders? | 2022 Jun |
2 |
| 2 |
35440293 | Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT. | 2022 Apr 19 |
1 |
| 3 |
35615325 | Treatment of Indolent and Advanced Systemic Mastocytosis. | 2022 |
1 |
| 4 |
32972961 | Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. | 2021 Jan |
1 |
| 5 |
33301227 | Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. | 2021 Apr |
1 |
| 6 |
33320833 | Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment. | 2021 Jan 25 |
1 |
| 7 |
33453089 | Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. | 2021 Apr |
3 |
| 8 |
33740926 | Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. | 2021 Mar 19 |
1 |
| 9 |
33804174 | Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. | 2021 Mar 15 |
1 |
| 10 |
33876372 | Gastrointestinal stromal tumor: a review of current and emerging therapies. | 2021 Jun |
1 |
| 11 |
34023541 | The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation. | 2021 Jun |
1 |
| 12 |
34289787 | Avapritinib for Systemic Mastocytosis. | 2021 Aug |
2 |
| 13 |
34343033 | Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. | 2021 Oct 1 |
2 |
| 14 |
34729266 | The Role of Avapritinib for the Treatment of Systemic Mastocytosis. | 2021 Sep |
1 |
| 15 |
34873347 | Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. | 2021 Dec |
1 |
| 16 |
32346366 | Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap. | 2020 |
1 |
| 17 |
32517495 | Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. | 2020 Aug |
2 |
| 18 |
32541319 | New drugs in gastrointestinal stromal tumors. | 2020 Jul |
1 |
| 19 |
32615108 | Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. | 2020 Jul |
2 |
| 20 |
32821296 | Successful treatment with avapritinib in patient with mucosal metastatic melanoma. | 2020 |
4 |
| 21 |
30274985 | Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors. | 2019 Jan 15 |
3 |
| 22 |
31033566 | New therapeutic agents in gastrointestinal stromal tumours. | 2019 Jul |
1 |
| 23 |
31117741 | Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. | 2019 Jul 1 |
2 |
| 24 |
31372066 | Novel approaches to treating advanced systemic mastocytosis. | 2019 |
1 |
| 25 |
29233825 | Rapid Responses to Avapritinib (BLU-285) in Mastocytosis. | 2018 Feb |
1 |
| 26 |
29964125 | Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. | 2018 Nov |
1 |
| 27 |
30007460 | Kit Mutations: New Insights and Diagnostic Value. | 2018 Aug |
1 |
| 28 |
30155614 | Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis. | 2018 Oct |
1 |